Shanghai Shyndec Pharmaceutical plans to raise CNY2.03bn ($307.41m) through the private placement of convertible bonds.
The bonds have a maturity period of six years from the issued date.
Headquartered in China, Shanghai Shyndec is a manufacturer of active pharmaceutical ingredients (APIs), chemical raw materials, and finished drug products.
Aprecia Pharmaceuticals has collaborated with Cycle Pharmaceuticals to develop and commercialise ZipDose 3D-printed orphan drugs using the former’s FDA-approved 3DP ZipDose technology platform.
Based in the US, Aprecia Pharmaceuticals is a drug delivery technology company, while Cycle Pharmaceuticals is a UK-based pharmaceutical company.
Japanese pharmaceutical products manufacturer Daiichi Sankyo Company and Puma Biotechnology have signed a pre-clinical research agreement with Memorial Sloan Kettering Cancer Center (MSK).
Daiichi Sankyo’s investigational drug conjugate DS-8201 and Puma Biotech’s tyrosine kinase inhibitor neratinib (NERLYNX) will be investigated in HER2-mutated or HER2-positive solid tumours, as part of the agreement.
Veru has acquired the global rights for oral granule formulation solifenacin from Camargo Pharmaceuticals Services.
Solifenacin is the API in VESIcare, a drug used for treating overactive bladder in men and women.
The acquisition allows Viru to enhance its novel urology drugs portfolio.